GE to Retain Amersham s Biosciences Unit; Provides Glimpse Into PGx Plans | GenomeWeb

Can General Electric make Amersham a “mainstream” healthcare player? This has become one of GE’s main goals as the giant conglomerate absorbs the British life sciences-tool company and sets its sights on personalized medicine.

Broadly, GE hopes to put to work the early-stage discovery technologies found in Amersham’s Biosciences unit in order to develop molecular diagnostics platforms that can be used arm in arm with its imaging tools in the “mainstream” healthcare setting.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Familial DNA searches in criminal cases are winning over some critics, the Los Angeles Times reports.

In Nucleic Acids Research this week: ProTraits includes genetic, phenotypic data on bacteria, archaea; Candida albicans assembly 22; and more.

The Wall Street Journal reports that researchers are looking beyond Cas9 for CRISPR editing.

In PNAS this week: miR-515 levels higher in women with preeclampsia, horizontal gene transfer in parasitic plants, and more.